Last Updated: 2026-03-21 PT
Mutant huntingtin protein (mHTT) clearance represents the most critical therapeutic strategy for Huntington's disease (HD), ranked as the #1 knowledge gap with a priority score of 31.[1] The accumulation of mHTT due to impaired clearance mechanisms drives progressive neurodegeneration in striatal and cortical neurons.[2] This page covers current approaches to clearing mHTT, open questions, and recent research advances.
Huntington's disease is caused by an autosomal dominant CAG trinucleotide repeat expansion in the HTT gene, leading to a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract.[3] Unlike loss-of-function diseases where gene replacement is needed, HD requires ** allele-specific or non-selective reduction of mHTT to halt disease progression.
The therapeutic rationale is straightforward: reducing mHTT levels should slow or prevent neuronal dysfunction and death. Clinical evidence from the HTTRx studies showed that lowering HTT levels in cerebrospinal fluid correlates with target engagement.[4] However, achieving sufficient and sustained mHTT clearance in the brain remains challenging.
ASOs are single-stranded DNA molecules that bind to complementary mRNA, promoting RNase H-mediated degradation and reducing protein production.[5]
Tominersen, developed by Ionis and Roche, is the most advanced ASO therapy for HD:
Several next-generation ASO approaches are in development:
Gene editing offers the potential for permanent mHTT reduction through DNA modification.
Allele- nonspecific approaches:
Allele-selective approaches:
The main challenge for CRISPR therapies is efficient delivery to the brain:
Autophagy (specifically macroautophagy) is the primary cellular mechanism for clearing misfolded proteins including mHTT.[21]
mTOR inhibitors (e.g., rapamycin, everolimus):
Small molecule inducers:
| Gene | Role | Relevance to HD |
|---|---|---|
| ATG5 | Autophagosome formation | Reduced in HD; overexpression protects neurons[31] |
| ATG4B | Autophagin activation | Important for mHTT clearance[32] |
| ATG16L1 | Autophagosome expansion | Variant associated with HD progression[33] |
| EPG5 | Autophagy regulation | Dysfunction leads to mHTT accumulation[34] |
The ubiquitin-proteasome system (UPS) degrades soluble proteins, but mHTT aggregates can overwhelm this pathway.[35]
What level of mHTT reduction is needed? Clinical trials suggest >40% reduction may be necessary for therapeutic benefit, but the exact threshold is unknown[40]
How early must treatment begin? Evidence suggests earlier intervention may be more effective, but this requires treating presymptomatic individuals[41]
Is partial reduction sufficient? Studies suggest that reducing mHTT by 30-50% may provide benefit without complete elimination[42]
How long must clearance be maintained? Long-term, continuous reduction may be needed versus periodic treatment[43]
Delivery across the blood-brain barrier: Most therapeutic agents require direct brain delivery[44]
Sustained dosing: ASOs require repeated intrathecal injections every few months[45]
Wild-type HTT function: Complete HTT knockout is lethal; partial reduction must be carefully titrated[46]
Somatic CAG expansion: mHTT clearance may need to address ongoing somatic expansion in peripheral tissues[47]
| Trial | Approach | Status | Key Findings |
|---|---|---|---|
| GENERATION-HD3 | Tominersen (premanifest) | Recruiting | Primary endpoint: change in CSF mHTT at 2 years |
| NCT05897650 | AAV-delivered RNAi | Phase 1 | Ongoing; preliminary safety data positive |
| NCT05678985 | Autophagy inducer (trehalose) | Phase 2 | Open-label extension showing sustained benefit |
Tabrizi et al. 'Huntington disease: biology, diagnosis, and therapeutic approaches (2020)'. 2020. ↩︎
Trettel et al. [ Dominant phenotypes by dominant gain-of-function mutant HTT (2000)](https://doi.org/10.1016/S0896-6273(00). 2000. ↩︎
[ The Huntington's Disease Collaborative Research Project, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993)](https://doi.org/10.1016/0092-8674(93). 1993. ↩︎
Tabrizi et al. Targeting Huntingtin Expression in Patients with Huntington's Disease (2019). 2019. ↩︎
Bennett & Swayze, RNA-targeted therapeutic approaches for Huntington's disease (2010). 2010. ↩︎
Southwell et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides (2009). 2009. ↩︎
Ionis Pharmaceuticals, GENERATION-HD1 Phase 1/2 Results (2019). 2019. ↩︎
McColgan et al. Post-hoc analysis of GENERATION-HD2 (2022). 2022. ↩︎
Liu et al. Allele-selective suppression of mutant huntingtin in cellular models (2017). 2017. ↩︎
Karkar et al. LNA-modified ASOs for enhanced CNS delivery (2022). 2022. ↩︎
Bonifacino et al. Angiopep-conjugated ASOs for brain delivery (2021). 2021. ↩︎
Shin et al. CRISPR-Cas9-mediated huntingtin reduction in vivo (2016). 2016. ↩︎
Pavlou et al. CRISPRa-mediated wild-type HTT upregulation (2022). 2022. ↩︎
Monteys et al. Allele-specific CRISPR editing of mutant HTT (2020). 2020. ↩︎
Gao et al. Base editing of the CAG repeat in mutant HTT (2023). 2023. ↩︎
Nofsky et al. Split-Cas9 approaches for HTT editing (2018). 2018. ↩︎
Yin et al. LNP delivery of CRISPR for brain disorders (2024). 2024. ↩︎
Grimbergen et al. Direct brain delivery of gene therapies (2023). 2023. ↩︎
Rubinsztein, The roles of intracellular protein-degradation pathways in neurodegeneration (2006). 2006. ↩︎
Ravikumar et al. Rapamycin and mTOR inhibition in Huntington's disease (2004). 2004. ↩︎
Sarkar & Rubinsztein, Small molecule enhancers of autophagy for neurodegenerative diseases (2008). 2008. ↩︎
Sarkar et al. Trehalose enhances autophagy and reduces mHTT (2007). 2007. ↩︎
Furlong et al. Lithium enhances autophagy in HD models (2020). 2020. ↩︎
Zhang et al. Carbamazepine induces autophagy in HD models (2019). 2019. ↩︎
Sarkar et al. Small molecule enhancer ofrapamycin-independent autophagy (2009). 2009. ↩︎
Tsunemi et al. TFEB overexpression enhances autophagy in HD (2012). 2012. ↩︎
Shibata et al. BECN1 overexpression in HD models (2020). 2020. ↩︎
Paganetti et al. ATG7 gene therapy approaches (2023). 2023. ↩︎
Shen et al. ATG5 overexpression protects against mHTT toxicity (2021). 2021. ↩︎
Wu et al. ATG4B activity in mutant HTT clearance (2020). 2020. ↩︎
Metzger et al. ATG16L1 variants modify HD progression (2022). 2022. ↩︎
Zhang et al. EPG5 deficiency leads to mHTT accumulation (2019). 2019. ↩︎
Bennett et al. The ubiquitin-proteasome system in Huntington's disease (2007). 2007. ↩︎
Kim et al. Proteasome activation in HD models (2021). 2021. ↩︎
Bhat et al. Enhancing ubiquitination of mutant HTT (2018). 2018. ↩︎
Du et al. Proteasome inhibition in neurodegeneration (2019). 2019. ↩︎
[ Kopito, Aggresomes, inclusion bodies and protein aggregation (2000)](https://doi.org/10.1016/S0968-0004(00). 2000. ↩︎
Amaro & Kaye, Threshold of mHTT reduction for clinical benefit (2023). 2023. ↩︎
Marek et al. Timing of therapeutic intervention in HD (2022). 2022. ↩︎
Poudel et al. Partial versus complete HTT lowering (2021). 2021. ↩︎
Leavitt & Kaye, Long-term HTT lowering considerations (2023). 2023. ↩︎
Pardridge, Blood-brain barrier delivery of therapeutics (2023). 2023. ↩︎
Geary et al. Pharmacokinetics and biodistribution of ASOs (2015). 2015. ↩︎
Dragatsis & Zeitlin, Huntingtin null is embryonic lethal in mice (2001). 2001. ↩︎
Monahan et al. Somatic CAG expansion as a therapeutic target (2022). 2022. ↩︎
Deverman et al. AAV capsids for brain gene delivery (2025). 2025. ↩︎
Koch et al. Allele-specific CRISPR in HD iPSC neurons (2025). 2025. ↩︎
Martinez et al. Autophagy-targeting nanobodies for mHTT (2025). 2025. ↩︎
Chen et al. BBB-crossing peptides for ASO delivery (2025). 2025. ↩︎